In a report released yesterday, Allen Klee from Maxim Group maintained a Buy rating on Roadzen Inc, with a price target of $4.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Allen Klee has given his Buy rating due to a combination of factors that highlight Roadzen Inc’s potential for growth and financial improvement. The company has shown a narrowing of its adjusted EBITDA loss, which was better than expected, indicating effective cost control and a shift towards higher-margin segments. Additionally, Roadzen’s revenue has increased by 22% year-over-year, and the company is poised for further growth with the resurgence of GAP insurance in the UK and a strategic partnership in the U.S. to act as a managing general agent.
Another reason for the Buy rating is the promising outlook for fiscal year 2026, where Roadzen is expected to achieve double-digit revenue growth and turn adjusted EBITDA positive by the December quarter. The company’s innovative technologies, such as drivebuddyAI and MixtapeAI, are anticipated to drive efficiency and revenue. Furthermore, Roadzen’s valuation appears attractive compared to its peers, and management’s efforts to improve the balance sheet and target adjusted EBITDA breakeven within the next two quarters add to the positive outlook.
According to TipRanks, Klee is an analyst with an average return of -15.1% and a 28.63% success rate. Klee covers the Technology sector, focusing on stocks such as Castellum, Roadzen Inc, and Health In Tech, Inc. Class A.